Pfizer and Sangamo Therapeutics ally on haemophilia therapy research

Pfizer has announced an exclusive global collaboration and license agreement with Sangamo Therapeutics, focusing on a new treatment for haemophilia A.

The alliance will see both companies working together on the development and commercialisation of a number of gene therapy programmes for haemophilia A, including SB-525, one of Sangamo's four lead product candidates.

SB-525, which Sangamo expects to enter the clinic this quarter, has the potential to be a best-in-class therapy and has been granted orphan drug designation by the US Food and Drug Administration.

Dr Mikael Dolsten, president of worldwide research and development at Pfizer, said: "Sangamo brings deep scientific and technical expertise across multiple genomic platforms, and we look forward to working together to advance this potentially transformative treatment for patients living with haemophilia A."

Sangamo will receive a $70 million (54.2 million pounds) upfront payment from Pfizer and will be responsible for conducting the SB-525 phase I/II clinical study, as well as for certain manufacturing activities.

Pfizer will take operational and financial responsibility for all subsequent research, development, manufacturing and commercialisation activities for SB-525 and additional products, with Sangamo potentially eligible to receive milestone payments of up to $475 million.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.